Nancy J. Hutson - 19 May 2023 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc

Role
Director
Signature
/s/ Jonathan P. Mow, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
19 May 2023
Net transactions value
$0
Form type
4
Filing time
19 May 2023, 16:15:57 UTC
Previous filing
21 Nov 2022
Next filing
15 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHASQ Common Stock Options Exercise +3,750 +11% 37,510 19 May 2023 Direct F1
holding PHASQ Common Stock 4,000 19 May 2023 Held in an individual retirement account for the benefit of the Reporting Person

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHASQ Restricted Stock Units Options Exercise $0 -3,750 -100% $0.000000* 0 19 May 2023 Common Stock 3,750 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
F2 The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date.